The primary objective of the analysis was to compare duration of survival in patients who received bevacizumab plus 5FU/LV, irinotecan or oxaliplatin based chemotherapy with the survival rate in a combined control groups of patients who received the same protocols alone, without bevacizumab. Methods: Pooling of the data from the several studies allows evaluation of efficacy end points with greater statistical power to detect real differences between the groups of patients who were and were not treated with bevacizumab. The 10 studies have to be used for analysis were well designed, prospective trials conducted in patients with metastatic colorectal adenocarcinoma. Results: The median duration of survival was 18/12/11 months median duration of progression free survival was 8.8/7/6.7 months and response rate was 34/14/12% in the 5-FU/LV/bevacizumab group, 5-FU/LV CI group, and bolus 5-FU/LV group, respectively. Difference in OS for patients who received bevacizumab with 5-FU/LV in comparison to 5-FU/LV alone is up to 7 months. The median duration of survival for bevacizumab plus irinotecan-based chemotherapy was 20 months, median duration of progression free survival was 11 months and response rate was 45%. Difference in OS, PFS and RR for patients who received bevacizumab plus irinotecan-based chemotherapy in comparison to irinotecan-based chemotherapy alone is up to 5 months, 4.5 months and 10%. For oxaliplatinbased protocols tumor response was 43-53%, overall survival was 16.4-19.4 months and the median progression free survival was 8-9 months. The median duration of survival was 26 months (benefit is up to 10 months), median duration of progression free survival was 19 months (benefit is up to 10 months) and response rate was 59% (benefit is up to 16%) were achieved for bevacizumab plus FOLFOX4 (oxaliplatin/inf.5FU/LV).
INTRODUCTION

I
rinotecan-based regimens such as IFL offer improved antitumor efficacy and survival relative to 5-FU-based chemotherapy. However, some patients with metastatic CRC are not appropriate candidates for irinotecan, either because of its toxicity, particularly neutropenia and delayed diarrhea, or because they have characteristics suggesting they are less like to benefit. Predictors of a poorer response or increased toxicity to irinotecan include advanced age, low performance status, and low serum albumin level 1 . Oxaliplatin-based regimens such as FOLFOX (oxaliplatin and infused 5FU/LV) offer an alternative, but both acute and chronic neurotoxicity associated with oxaliplatin may be limiting 2 . Based on these observations, various regimens have emerged as standard option in first-line therapy, including the use of 5FU/LV for selected patients who are not considered optimal candidate for irinotecan-or oxaliplatin-based therapies.
Bevacizumab is an anti-VEGF, humanized mAb that is the most advanced agent of its class in clinical development. Several studies have examined bevacizumab in combination with chemotherapy in the first-and secondline settings in patients with metastatic CRC. Phase II or III trials of bevacizumab in combination with 5-fluorouracil/leucovorin (5-FU/LV), irinotecan, and oxaliplatin are completed or ongoing [3] [4] [5] [6] . Most of these studies show clinical benefit including benefit in survival for bevacizumab treated patients. Inspite of that, there is lack of information concerning the extent to which bevacizumab can be used to treat metastatic CRC. We still need more evidence related to efficacy and safety of bevacizumab in different settings or sequential treatments. Pooling data from the several studies allows evaluation of efficacy end points with greater statistical power to detect real differences between the groups of patients who were and were not treated with bevacizumab. The primary objective of the analysis was to compare duration of survival in patients who received bevacizumab plus 5FU/LV, irinotecan or oxaliplatin based chemotherapy with the survival rate in a combined control groups of patients who received the same protocols alone, without bevacizumab.
PATIENTS AND METHODS
Study design of analyzed trials
The studies used for analysis were well designed, prospective trials conducted in patients with histologically verified locally advanced disease and/or metastatic colorectal adenocarcinoma, without possibility for surgical resection. The diagnosis of locally advanced or metastatic unresectable disease was based on computed tomographic (CT) scan evaluation.
Only chemotherapy-naïve patients with measurable disease were eligible for the treatment in those studies. Other inclusion criteria were: ECOG performance status 0-2, and normal bone marrow, liver and renal function. Informed consent was obtained from all patients.
Study1. In the meta-analysis 7 , individual data of 1219 patients from 6 randomized trials served as the basis for this meta-analysis, which was conducted by an independent secretariat in close collaboration with the investigator.
This meta-analysis was performed to assess benefit in survival and response rate for patients who received bolus and continuous infusion (CI) of 5FU/LV in the first line chemotherapy of metastatic CRC. Study 2. This phase III trial 3 was conducted in 813 patients who were randomized to receive IFL plus bevacizumab (5mg/kg) vs. IFL alone. Primary end point was overall survival. Progression-free survival, the response rate, the duration of response, safety and the quality of live were secondary end points. Study 3. In this study 8 193 patients were assigned to receive 5-FU/LV, irinotecan and oxaliplatin in five different sequential treatment groups.
Primary end point was overall survival; secondary were the response rate and time to progression. Study population was enrolled in Serbia, and we used study data as a reference data for efficacy of chemotherapy without bevacizumab in Serbian population.
Study 4. This controlled, prospective multicentre study 9 enrolled 30 patients in Serbia treated with bevacizumab (5mg/kg) in combination with irinotecan-, oxaliplatin-, or 5FU/LV based protocols. Overall survival was primary end point. Study 5 . In this open-label, randomized, multicentric study 10 387 patients previously untreated with chemotherapy for advanced CRC were randomly assigned to irinotecan plus 5FU/LV or 5FU/LV alone. Infusion schedule was once weekly or every 2 weeks, and were chosen by each centre. They assessed response rate and time to progression, and also response duration, survival and quality of life.
Study 6. This EORTC phase III study 11 randomly assigned 430 patients to receive infusional 5-FU/LV with or without irinotecan. Progression free survival, overall survival, and response rate were study end points. Study 7. In this phase III trial 12 200 patients from 15 institutions in 4 countries were randomly assigned to receive infusional 5-FU/LV with or without oxaliplatin. Progression free survival, overall survival and response rate were measured. Study 8. This phase III trial 2 randomized 420 patients to receive infusional 5-FU/LV with or without oxaliplatin. Progression free survival was primary end point. Overall survival and response rate were measured, too. Study 9. In the TREE 2 study 13 223 patients received bevacizumab with different oxaliplatin-based chemotherapy. Overall survival, time to progression and response rate were measured. Study 10. In this analysis 4 249 patients were received bolus 5FU/LV/bevacizumab. Duration of survival, progression free survival and response rate were measured.
Statistical consideration
Duration of survival was defined as time from randomization to death from any cause. The time to progression or progression free survival was calculated from randomiza- Response rate was calculated on an intention-to-treat basis. Statistical analysis included Kaplan-Meier method for estimation of overall survival and time to progression and the long-rank test to assess the differences in overall survival and time to progression between the treatment groups.
RESULTS
Bevacizumab and 5-FU/LV
A total of 1662 patients treated with 5FU/LV in studies number 1, 3, and 10, were analyzed. Tumor response was 22% for patients assigned to 5-FU/LV CI and 14% for patients assigned to 5-FU/LV bolus. Tumor response for patients treated with 5-FU/LV bolus in Serbia was 12%. Overall survival was significantly higher in patients assigned to 5-FU/LV CI (median 12 months) vs. 5-FU/LV bolus (11 months) (HR 0.88; 95%CI 0.78 to 0.93; P=0.04).
The median survival duration for 5-FU/LV bolus patients treated in Serbia was 11 months, with median progression free survival of 7 months. The median duration of survival was 18 months in the bolus 5-FU/LV/bevacizumab group, median duration of progression free survival was 8.8 months and response rate was 34%. Efficacy data presented in Table 1 .
Bevacizumab and irinotecan-based chemotherapy
A total of 1488 patients treated with different irtinotecan-based chemotherapy with or without bevacizumab in studies number 2, 3, 5, and 6, were analyzed. Only study number 2 was randomized phase III trial compared IFL vs. IFL plus bevacuzimab. ILF protocol consist of irinotecan plus bolus 5-FU/LV.
All other studies used combination of irinotecan plus continuous infusion of 5-FU/LV (e.g. FOLFIRI) which are significantly efficacious than bolus 5-FU/LV plus irinotecan protocols like IFL. For irinotecan-based protocols tumor response was 22-62%, overall survival was 15.6-20.1 months and the median progression free survival was 6.2-9 months.
The only data for bevacizumab plus IFL can be from study number 2. The median duration of survival was 20.3 months, median duration of progression free survival was 10.6 months and response rate was 44.8%. Efficacy data presented in Table 2 .
Bevacizumab and oxaliplatin-based chemotherapy
A total of 706 patients treated with different oxaliplatinbased chemotherapy with or without bevacizumab in studies number 3, 7, 8, and 9, were analyzed. For oxaliplatinbased protocols tumor response was 43-53%, overall survival was 16.4-19.4 months and the median progression free survival was 8-9 months. The median duration of survival of 26 months, median duration of progression free survival of 19 months and response rate of 59% were achieved for bevacizumab plus FOLFOX4 (oxaliplatin/inf.5FU/LV). Efficacy data presented in Table 3 .
Bevacizumab in combination with oxaliplatin, irinotecan and fluoropyrimidine-based therapy in Serbia
Thus far, only one study with bevacizumab has been performed in Serbia 9 . The aim of this study was to investigate efficacy and safety of bevacizumab added to different chemotherapy in patients with metastatic CRC. This was a controlled, prospective, multicentre, national, cohort study. Thirty patients with advanced colorectal cancer were enrolled. Bevacizumab was applied with oxaliplatin, irinotecan-, 5FU-or capecitabine -based chemotherapy in the first-, second-or third-therapy lines. A total of 261 cycles were applied. The median number of applied cycles per patient was 8 (range 2-16). Objective tumor response was seen in 11 patients 37% (95%CI 19-69%) calculated on an intention-to-treat basis. The median duration of response was 12 months. Three of 11 patients (27%) with partial remission (PR) had secondary surgery. Response rate (RR) was seen in 9 of 16 patients (56%) who received bevacizumab in the first-line treatment and in 2 of 14 patients (14%) who received therapy in the second+ lines (p=0.02). Clinical benefit (PR+stable disease) was Br. 4 The addition of bevacizumab to fluoropyrimidine, 13 irinotecan and oxalipatin based therapy improves survival seen in 22 (74%) patients. 75% of patients achieved clinical benefit in the first-line and 74% in the second+ chemotherapy lines. The median time to progression (TTP) of the patients was 9 + months (95%CI 7 -+ h) at the moment of this analysis. The median TTP of patients who received bevacizumab in the first line was 11 months (95%CI 8 -+ h). The median TTP of patients who received bevacizumab in the second+ lines was 5.5 months (95%CI 4 -+ h) (p=0.015). The median survival time (OS) for all patients was 9 + months (95%CI 7 -+ h). The median OS at the moment of analysis was 11 months (95%CI 9 -+h) for patients receiving bevacizumab in the first line, and 7 months for patients receiving the drug in the second+ lines (95%CI 6 -+ h) (p=0.024). The incidence of any toxicity grade 3-4 was less than 10%. Bevacizumab associated incidence of grade 3-4 side effects did not exceed 5%. Hypertension 5% and thromboembolism 5% were the most frequent events. Gastrointestinal perforation did not occur. There was one toxic death due to sepsis which was not directly associated with bevacizumab toxicity. This study can not be used for combined analyses of efficacy because the median survival and time to progression have not been reached yet, but the results of this study can display benefit for patients who received bevacizumab in Serbia.
DISCUSSION
The combined analysis of pooled data from afore mentioned clinical trials demonstrate that the addition of bevacizumab to 5FU/LV, irinotecan, or oxaliplatin-based chemotherapy provides an important clinical benefit for the first-line treatment of advanced CRC. This benefit includes significant improvements in response rate, progression free survival, and most importantly, overall survival. The addition of bevacizumab to 5FU/LV improved survival by 6-7 months, progression-free survival by about 2 months, and response rate by nearly 22%. The addition of bevacizumab to irinotecan-based chemotherapy improved survival by nearly 5 months, progression-free survival by about 4.5 months, and response rate by 10%. The addition of bevacizumab to oxaliplatin-based chemotherapy improved survival by 7 to more than 10 months, progression-free survival by about 11 months, and response rate by up to 16%. Over the past few years, several new chemotherapy agents have demonstrated a survival benefit over long-standing "standard" therapy for the first-line CRC treatment: 5-FU modulated with leucovorin. Irinotecan provided a 2.2 month survival improvement when added to bolus 5-FU/LV 2 , but was associated with a significant increase in diarrhea. Oxaliplatin provided a 1.5 month improvement in survival when added to an infusional 5-FU/LV regimen, but was associated with significant increases in diarrhea, neutropenia, and clinically significant neurosensory toxicity 2 . Our combined analysis suggests that bevacizumab provides significant improvement in survival, with the most significant toxicity being an increase in clinically significant hypertension and thromboembolism. The impact of bevacizumab when added to 5-FU/LV, irinotecan and oxaliplatin-based chemotherapy, is also clinically important on the end points of progression-free survival and response rate.
As new agents have become available for patients with metastatic CRC, there has been logical evolution in the exploration of therapeutic combinations. Ongoing clinical trials are still evaluating the addition of bevacizumab to oxaliplatin and infused 5-FU/LV, as well as to irinotecan in combination with infusional 5-FU/LV, and capecitabine-based regimens containing oxaliplatin or irinotecan. Retrospective analyses have suggested that optimal patient outcome in metastatic CRC may be achieved by exposing patients to all active agents 15 . Because oxaliplatin and irinotecan have toxicities that may require treatment discontinuation in many patients, even in the setting of ongoing tumor control, regimens with planned sequences of agents are being explored and seem promising 16 . Bevacizumab can be used not only in the first chemotherapy line. In some studies bevacizumab has been also used for patients who receive chemotherapy in the second or following chemotherapy lines 9, 16 . The results of our study performed in Serbia suggest that bevacizumab should be used upfront rather than in second-line 9 .
Despite of advances made in the past decade, metastatic CRC has still has an inevitable fatal outcome except in a small percentage of selected patients, approximately 10-20%, who have good prognosis after successful complete operative removal of the liver metastases. In unresectable In conclusion, addition of bevacizumab to 5-FU/LV, irinotecan or oxaliplatin-based chemotherapy provides significant and clinically meaningful improvement in overall survival, disease-free survival and response rate compared with 5-FU/LV, irinotecan or oxaliplatin-based chemotherapy alone in patients with metastatic CRC. Further questions that have to be addressed or are currently being examined in clinical trials are the efficacy and safety of bevacizumab in neoadjuvant and adjuvant settings, what is the optimal dosage of bevacizumab, what is optimal or maximum number of cycles for which bevacizumab should be administered, and the farmacoeconomic impact of the use of bevacizumab in the treatment of CRC.
REZIME BEVACIZUMAB U KOMBINACIJI SA FLUORO-PIRIMIDINSKIM, IRINOTEKANSKIM I OKSALIPLAT-INSKIM HEMIOTERAPIJSKIM REIMIMA PRODUAVA PREIVLJAVANJE KOD BOLESNIKA SA METASTAT-SKIM KOLOREKTALNIM KARCINOMOM (CRC):KOM-BINOVANA ANALIZA EFIKASNOSTI
Kontekst: Primarni cilj analize bio je da uporedi pre'ivljavanje bolesnika le~enih bevacizumabom u kombinaciji sa 5FU/LV, irinotekanskim ili oksaliplatinskim hemioterapijskim re'imima, sa pre'ivljavanjem bolesnika le~enih hemioterapijom, bez bevacizumaba.
Metod: Pulovanje rezultata iz razli~itih studija omogu}ava evaluaciju efikasnosti sa ve}om statisti~kom snagom i nagla{ava razliku u rezultatima medju bolesnicima le~enih bevacizumabom i onih koji nisu le~eni bevacizumabom. Deset analiziranih prospektivnih studija su uklju~ile bolesnike sa metastatskim kolorektalnim adenokarcinomom.
Rezultati: Medijana pre'ivljavanja bila je 18/12/11 meseci, dok su rezultati medijane perioda bez progresije bolesti bili 8.8/7/6.7 meseci, a terapijski odgovor 34/14/12% u grupama koje su primale kombinaciju 5-FU/LV/bevacizumab, 5-FU/LV hemioterapiju, i bolusni 5-FU/LV. Razlika u pre'ivljavanju bolesnika le~enih bevacizumabom u kombinaciji sa 5-FU/LV u odnosu na bolesnike le~ene samo 5-FU/LV, iznosila je preko 7 meseci. Medijana pre'ivljavanja bolesnika le~enih bevacizumabom i irinotekanom bila je 20 meseci, medijana perioda bez progresije bolesti 11 meseci, a terapijski odgovor 45%.
Razlika u pre'ivljavanju, periodu bez progresije bolesti i terapijskom odgovoru kod bolesnika le~enih bevacizumabom i irinotekanom bila je ve}a za 5 meseci, 4.5 meseca i 10% u odnosu na bolesnike le~ene samo irinotekanom. Terapijski odgovor kod oksaliplatinskg protokola le~enja iznosio je 43-53%, ukupno pre'ivljavanje 16.4-19.4 meseci, dok je medijana perioda bez progresije bolesti bila 8-9 meseci.
Medijana pre'ivljavanja od 26 meseci (benefit do 10 meseci), medijana perioda bez progresije bolesti od 19 meseci (benefit do 10 meseci) i terapijski odgovor od 59% (benefit do 16%), predstavljaju rezultate koji su postignuti dodavanjem bevacizumaba FOLFOX4 hemioterapijskom re'imu (oksaliplatin-/inf.5FU/LV).
Zaklju~ak: Bevacizumab u kominaciji sa 5-FU/LV, irinotekanskim ili oksaliplatinskim hemioterapijskim re'imima, dokazao je klini~ki zna~ajno produ'avanje ukupnog pre'ivljavanja, perioda bez progresije bolesti kao i pove}anje terapijskog odogovora u odnosu na rezultate postignute terapijom 5-FU/LV, irinotekanskim ili oksaliplatinskim hemioterapijskim re'imima, kod bolesnika sa metastatskim CRC.
Klju~ne re~i: Bevacizumab, kolorektalni karcinom, hemioterapija.
